Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...
Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Both Edwards and JenaValve are currently developing transcatheter aortic valve replacement devices to treat patients with aortic regurgitation (“AR”). According to the Complaint, over 8 million ...
Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps ...
At the EuroPCR 2025, Edwards Lifesciences EW has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 ...
Edwards, AtriCure, Boston Scientific, and Medtronic report strong earnings driven by TAVR, PFA, and cardiac ablation growth in 2025.
In the first quarter, the company reported TAVR sales of $1.05 billion, which grew 3.8% versus the prior year, 5.4% on a constant currency basis, or 6.5% further adjusted for one less billing day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results